BioNTech shares closed over 8% in trading Friday after announcing positive Phase 3 trial results for a breast cancer drug developed with Duality Biologics.

#BNTX #BioNTech #BNTXStock #BNTXNews #BNTXStockNews #BioNTechStock #BioNTechNews #BioNTechStockNews #DualityBio #BreastCancer #CancerResearch

BioNTech & Bristol Myers Ink $11.1B Cancer Drug Pact

#BNTX #BNTXStock #BNTXNews #BNTXStockNews #BMY #BMYStock #BMYNews #BMYStockNews #BioNTech #BioNTechStock #BioNTechNews #BioNTechStockNews #BristolMyersSquibb #BristolMyersSquibbStock #BristolMyersSquibbNews #BristolMyersSquibbStockNews #BristolMy